MOTS-c Peptide Shows Promise for Autism Symptoms in Rat Model
Background
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by challenges in social interaction, communication, and repetitive behaviors, affecting millions globally. Current therapeutic options primarily focus on symptom management, highlighting a critical need for treatments that address underlying neurological dysfunctions. This study addresses the knowledge gap by investigating the therapeutic potential of the mitochondrial-derived peptide MOTS-c in an established animal model of autism, exploring its impact on key neurobiological pathways.
Results
The study revealed significant improvements in autistic-like behaviors and neurochemical markers in the MOTS-c treated group. Specifically, MOTS-c treatment led to a 38% increase in social interaction time (p<0.01) and a 45% reduction in repetitive grooming behaviors (p<0.001) compared to the untreated VPA group. Biochemical analysis showed that BDNF levels in the prefrontal cortex were restored, demonstrating a 2.3-fold increase in the MOTS-c group compared to VPA controls (p<0.001). Furthermore, tetrahydrobiopterin levels, crucial for neurotransmitter synthesis, were significantly elevated by 1.8-fold in the MOTS-c treated animals (p<0.05), indicating a positive impact on neurochemical balance. > The most important finding was the comprehensive reversal of core autistic-like behaviors alongside the restoration of critical neurotrophic factors and neurotransmitter cofactors, suggesting a multifaceted therapeutic mechanism for MOTS-c.
Why It Matters
This research highlights MOTS-c as a promising novel therapeutic candidate for Autism Spectrum Disorder, potentially addressing both behavioral symptoms and underlying neurobiological deficits. The ability of MOTS-c to modulate BDNF and tetrahydrobiopterin pathways suggests a broad neuroprotective and neurodevelopmental role. This study provides strong preclinical evidence, paving the way for future human clinical trials to evaluate MOTS-c's efficacy and safety in individuals with autism. Further research, including Phase I and II human trials, is warranted to translate these findings into clinical practice.